SEC Form 4 · accession 0001358403-19-000020
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shane Ward
Officer — Sr. VP and General Counsel
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.35 | Feb 1, 2019 | A | 45,000 | A | — | Jan 31, 2029 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Remarks
EXHIBIT LIST: EX-24 Power of Attorney